Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease

Background: Transcranial ultrasound may be used to detect increased iron levels of the substantia nigra (SN) in patients with Parkinson disease (PD) and in control subjects. It is not known whether iron accumulation in PD is a primary or secondary phenomenon. However, sequence variations in genes involved in iron metabolism have been linked to basal ganglia disorders. One of these is ceruloplasmin (Cp), which is vitally involved in iron transport across the cell membrane. Methods: One hundred seventy-six patients with PD according to the UK Brain Bank criteria and 180 ethnically matched control subjects, who were previously examined for SN iron signal changes by transcranial ultrasound, were examined for mutations in the Cp gene using denaturing high-performance liquid chromatography and subsequent sequencing for verification of unequivocal signals. Immunohistochemistry of PD midbrains was performed to examine the presence of Cp in Lewy bodies. Results: Five novel missense variations were detected. One of these (I63T) was found in a single PD patient. A known variation (D554E) was significantly associated with PD and the ultrasound marker for increased SN iron levels. Moreover, a third sequence variation (R793H) was found to segregate with the ultrasound marker for increased iron levels in patients and control subjects. Immunohistochemistry demonstrated that Cp co-localizes with Lewy bodies in PD. Conclusions: Detection of sequence variations in a single Parkinson disease (PD) patient or associated with the ultrasound marker for increased substantia nigra iron levels and the presence of ceruloplasmin (Cp) immunoreactivity in Lewy bodies underline a suspected role for Cp in the pathogenesis of PD. Further functional analyses are warranted to investigate whether these variations are causally linked to the complex pathogenesis of PD in a subset of cases.

[1]  P. Bauer,et al.  Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra , 2003, Neuroscience Letters.

[2]  S. David,et al.  Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.

[3]  H. Miyajima,et al.  Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. , 2002, Blood cells, molecules & diseases.

[4]  U. Bonuccelli,et al.  Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. , 2002, Blood.

[5]  Jean-Pierre Julien,et al.  Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.

[6]  M. Won,et al.  The ceruloplasmin and hydrogen peroxide system induces α-synuclein aggregation in vitro , 2002 .

[7]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[8]  R. Benecke,et al.  Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.

[9]  H. Miyajima,et al.  Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation , 2001, Neurology.

[10]  Daniela Berg,et al.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.

[11]  Y. Ke,et al.  Rethinking the role of ceruloplasmin in brain iron metabolism , 2001, Brain Research Reviews.

[12]  H. Miyajima,et al.  Defective electron transfer in complexes I and IV in patients with aceruloplasminemia , 2000, Journal of the Neurological Sciences.

[13]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[14]  A. Nakamura,et al.  Increased lipid peroxidation in the brains of aceruloplasminemia patients , 2000, Journal of the Neurological Sciences.

[15]  H. Miyajima,et al.  Aceruloplasminemia with a novel mutation associated with parkinsonism , 2000, Neurogenetics.

[16]  S. David,et al.  Alternative RNA Splicing Generates a Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin in Mammalian Brain* , 2000, The Journal of Biological Chemistry.

[17]  J. Gitlin,et al.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G Becker,et al.  Vulnerability of the nigrostriatal system as detected by transcranial ultrasound , 1999, Neurology.

[19]  J. Snaedal,et al.  Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. , 1999, Pharmacology & toxicology.

[20]  T. Kawanami,et al.  Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain , 1999, Neurology.

[21]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[22]  C. Ríos,et al.  Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease , 1999, Neuroscience Letters.

[23]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .

[24]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.

[25]  P. Fox,et al.  Role of ceruloplasmin in cellular iron uptake. , 1998, Science.

[26]  B. N. Patel,et al.  A Novel Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin Is Expressed by Mammalian Astrocytes* , 1997, The Journal of Biological Chemistry.

[27]  J. Gitlin,et al.  Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. , 1996, Human molecular genetics.

[28]  R. MacGillivray,et al.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G Becker,et al.  Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.

[30]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[31]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[32]  T. Gasser Overview of the genetics of parkinsonism. , 2003, Advances in neurology.

[33]  J. Gitlin,et al.  Ceruloplasmin metabolism and function. , 2002, Annual review of nutrition.

[34]  M. Won,et al.  The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. , 2002, Biochimie.

[35]  D. Berg,et al.  Brain iron pathways and their relevance to Parkinson's disease. , 2001, Journal of neurochemistry.